TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, ages 65-80, with a BMI ≥ 27 and at least one of the following additional risk factors will be included: 1) Large waist circumference (\> 40 inches men, \>35 inches women) 2) hypertension or taking hypertension medication; 3) elevated lipids or taking medication for lipids or triglycerides 4) pre-diabetes (fasting glucose ≥ 100 mg/dL and \< 126 mg/DL OR 5) or a score of 15 on the American Diabetes Association (ADA) risk test.~All study participants must have access to a telephone (including appropriate assistive devices if there are hearing impairments) and be able to read at the 6th grade level.~Exclusion Criteria:~* Individuals who report that they have been diagnosed by their doctor with diabetes or that they are taking any medicines used to treat diabetes~* lack of physician clearance for exercise participation before the 4th session~* a weight loss of 4.5 kgs or more in the past six months (to rule out unintentional weight loss that may be an indicator of current or incipient physical illness)~* current use of weight loss medications~* unable to attend at least 75% of the GLB 12-session program or are unwilling to self-monitor food, activity and weight as prescribed will be excluded and encouraged to consider joining in subsequent years.~Excluded individuals are referred to other clinical resources as appropriate.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Group Lifestyle Balance plus phone contacts (Type: ACTIVE_COMPARATOR): Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
- Group Lifestyle Balance plus newsletter contacts (Type: PLACEBO_COMPARATOR): Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infants with PWS genetically confirmed~* Aged less than 5 months~Exclusion Criteria:~* Infants presenting hepatic insufficiency~* Infants presenting renal insufficiency~* Infants with abnormal ECG

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 5 Months
- Healthy Volunteers: f

Study Arms:
- first arm (Type: ACTIVE_COMPARATOR): 4IU of oxytocin every other day
- second arm (Type: ACTIVE_COMPARATOR): 4 IU of oxytocin daily
- third arm (Type: ACTIVE_COMPARATOR): 4 IU of oxytocin twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient aged ≥ 18 ans.~2. Signed inform consent~3. Obesity defined by a BMI value ≥ 30 kg/m2.~4. Hospitalized for :~   * acute medical affection such as :~     * congestive heart failure (stage III or IV NYHA),~    * severe respiratory disease,~    * Infectious disease or acute rheumatologic disorder or inflammatory bowel disease with one or more additional risk factors, including active cancer, previous VTE, age \> 75 y-o, estrogen therapy, chronic heart failure or chronic respiratory disease~  * or recent myocardial infarction(\< 6 weeks), recent stroke with hemiparesis (\< 15 days), previous VTE, myeloproliferative syndrome associated with one or more additional risk previously cited.~5. Affiliation to a welfare system.~Exclusion Criteria:~1. Subjects unwilling or unable to comply with study procedures~2. History of hypersensitivity to enoxaparin heparin induced thrombocytopenia~3. Previous history of heparin induced thrombopenia~4. acquired or inherited bleeding diathesis or coagulopathy,~5. Platelet count \< 50.000 G/L,~6. History of clinically significant bleeding~7. Severe renal insufficiency with CrCl \<30 ml/min (Cockcroft method),~8. Pregnancy or breastfeeding~9. Women without contraceptive methods~10. Severe peripheral arterial disease (Ankle blood pressure \<50mm Hg)~11. Concomitant anticoagulant therapy~12. Severe psychiatric disease~13. History of disease or psychological or sensory anomaly susceptible to prevent the subject to understand indeed the conditions required for his participation to the protocol or preventing him from giving its enlightened consent~14. Person deprived of liberty by an administrative or judicial decision, or person under legal guardianship person~15. Patient participating to a trial or having participated in another medicinal trial within 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin 40mg/ day (Type: ACTIVE_COMPARATOR): Enoxaparin administrated at the following dose : 40mg/ day
- Enoxaparin 60 mg/day (Type: EXPERIMENTAL): Enoxaparin administrated at the following dose : 60 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Phonation and Vocal Rest Programs After Acute Vocal Exertion in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* within age range~Exclusion Criteria:~* Voice Disorders~* Strong gag reflex~* Craniofacial disorders~* Cognitive Impairments~* Head and Neck Cancer~* Hearing Difficulties~* Dentition problems that prevent an oral scope being placed in mouth

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Adults (Type: EXPERIMENTAL): Participants will complete vocal rest and controlled phonation
- Healthy Adults reporting Vocal Fatigue (Type: EXPERIMENTAL): Participants will complete vocal rest and controlled phonation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 2 Diabetes Mellitus inadequately controlled at least 3 months on premixed insulin with 1 or 2 OADs~* 7.5 ≤ HbA1c ≤ 9.5%~* FPG ≥6.7 mmol/L~* History of Diabetes mellitus ≤10 years~* Premix insulin daily dosage ≤ 50 IU/Day~Exclusion Criteria:~* Type 1 Diabetes Mellitus~* Former treated on TZD~* Pregnancy / Lactation~* Creatine ≥1.5 mg/dl~* Hepatic disease, jaundice,or ALT/AST≥ 2.5 times of normal range~* Hormone therapy,~* Acute status of Diabetes complications~* Severe concomitant disease or complications with high risk of unexpected fatal events, like Myocardial Infarct, stroke, heart failure.~* Allergic to insulin glargine or any ingredient~* Participation in another clinical trial within 3 months~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effectiveness Study of JUVÉDERM VOLUMA® XC Injectable Gel for Chin Augmentation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chin retrusion~* In good general health~Exclusion Criteria:~* Permanent facial implants on the face and/or neck~* Received fat injections below the nose~* Tattoos, piercings, beard, mustache, and/or scars on the face below the nose~* Received semi-permanent dermal fillers in the chin or jaw line in the last 3 years~* Undergone dermal filler injections or had any surgery in the chin or jaw area in the last 2 years~* Received dermal filler injections in the lips or in the mouth area in the last 12 months~* Undergone mesotherapy or cosmetic treatment (e.g., laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, liposuction, lipolysis, or other ablative procedures) anywhere in the face or neck in the last 6 months~* Received botulinum toxin treatment below the nose in the last 6 months

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- JUVÉDERM VOLUMA® XC (Type: EXPERIMENTAL): JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
- No Treatment then JUVÉDERM VOLUMA® XC (Type: OTHER): No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Pre-cooling in Adolescent Tennis Athletes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adolescent athletes~Exclusion Criteria:~* Diagnosed chronic medical condition;~* Symptoms of acute illness;~* Recent (past 4 weeks) usage of medications known to affect the circulatory system, the thyroid, the pituitary function, or the metabolic status.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Pre-cooling scenario (Type: EXPERIMENTAL): One hour before a tennis match, the pre-cooling group was wearing a Cooling Cap (WElkins Sideline Cooling System, SCS) for 45 minutes.
- Sham evaluation (Type: SHAM_COMPARATOR): Participants were monitored during a usual game without any kind of pre-cooling strategy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must have a diagnosis of T2DM and be currently treated with PPAR gamma agent ((pioglitazone or rosiglitazone) and another anti-diabetes agent (metformin)~* Patients in the study must have a HbA1c between \>=7 and \<=10.5% and a fasting plasma glucose (FPG) \<270 mg/dL (15 mmol/L)~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* or a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Sitagliptin (Type: OTHER): Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy~* Was administered placebo to match SOF/VEL in Gilead study GS-US-342-1138~* HCV RNA ≥ 10\^4 IU/mL at screening~* Classification as treatment naive or treatment experienced~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~Key Exclusion Criteria:~* Current or prior history of clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.~* Screening electrocardiogram (ECG) with clinically significant abnormalities~* Laboratory results outside of acceptable ranges at screening~* Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically- or cytologically-confirmed diagnosis of advanced solid tumor.~2. Willing to provide tumor tissue for PD-L1 biomarker analysis.~3. At least one measurable lesion according to RECIST 1.1.~4. ECOG performance status of 0 to 1.~5. Life expectancy of more than 12 weeks.~6. Signing the informed consent forms.~7. Adequate bone marrow, liver and renal function.~Exclusion Criteria:~1. Subjects with untreated central nervous system (CNS) metastases.~2. Subjects with an active, known or suspected autoimmune disease.~3. Subjects with clinically significant cardiovascular and cerebrovascular diseases.~4. Subjects with high blood pressure who cannot be controlled well with antihypertensive drugs.~5. Subjects with previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency.~6. Subjects with arterial / venous thrombosis events occurred within 6 months of the first dose.~7. Subjects who have previously received anti-PD-1 / PD-L1 monoclonal antibody, anti-CTLA-4 monoclonal antibody, and VEGFR small molecule inhibitor therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- camrelizumab combined with famitinib (Type: EXPERIMENTAL): Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Cisplatin Combination Expansion:~Arm 1:Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting; Arm 2: Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting.~* Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination.~* Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination.~* Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination.~* Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.~* Eastern Cooperative Oncology Group \[ECOG\] performance must be 0 or 1.~* Adequate bone marrow, renal and liver function.~Exclusion Criteria:~* Prior therapy for Cisplatin Combination Expansion:~  * Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic setting;~ * Prior radiation to \>25% bone marrow as estimated by the Investigator.~* Patients with known symptomatic brain metastases.~* Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose.~* Major surgery within 4 weeks of the baseline disease assessments.~* \>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.~* Active bacterial, fungal or viral infection.~* Uncontrolled or significant cardiovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: EXPERIMENTAL): None
- Arm C (Type: EXPERIMENTAL): None
- Expansion Arm 1 (Type: EXPERIMENTAL): None
- Expansion Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole in Patients With a History of Bipolar Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Patients with a history of Bipolar I Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female Japanese subjects 18 to 49 years of age, defined as Japanese born in Japan, with both parents and 4 grandparents who wer born in Japan (family tree by history), and who have not lived outside of Japan for more than 5 years total (confirmed by passport or interview)~Exclusion Criteria:~* Participation in other studies involving investigational drug(s), investigational vaccines, or investigational medical devised within 28 days prior to study entry and/or during study participation. Participation in purely observational studies is acceptable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Prevnar 13 (Type: ACTIVE_COMPARATOR): 13 valent Pneumococcal Conjugate
- multivalent pneumococcal conjugate formulation 1 (Type: EXPERIMENTAL): multivalent pneumococcal conjugate formulation 1
- multivalent pneumococcal conjugate formulation 2 (Type: EXPERIMENTAL): multivalent pneumococcal conjugate formulation 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet ROME III Criteria~Exclusion Criteria:~* Constipation caused by:colonic etiology, pelvic floor dysfunction, metabolic disturbances, neurologic disturbances,concomitant medications affecting bowel function~* Chronic treatment with anticholinergics, narcotic analgesics~* Irritable Bowel Syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete